Among patients with psoriasis affecting special anatomical sites, IL-17 inhibitors are associated with significant improvements in PASI 75 and 90.

The ustekinumab biosimilar AVT04 has consistent efficacy through 28 weeks in patients with PsO with and without prior ustekinumab exposure.

Please provide your email address to receive an email when new articles are posted on . Tapinarof is a steroid-free topical treatment targeting atopic dermatitis. Patients saw statistically ...

Researchers compared eight severity score indices for C. difficile cases and found the Hines VA CDI severity score index showed the strongest correlation for predicting severe cases of CDI, according ...

Machine learning models may be able to more accurately predict psoriasis severity vs dermatologists using the Psoriasis Area and Severity Index and Body Surface Area measures. A systematic review ...

Use of a modified sleep apnea index can identify cardiovascular risk factors in adults with moderate to severe obstructive sleep apnea (OSA), according to results from a new study presented at the ...